GTP announced the continued expansion of its R&D partnership with Passage Bio, a Penn spinout focused on developing transformative therapies for central nervous system disorders. Passage Bio exercised two additional options with GTP, which focused on CNS diseases with high unmet need.
The Gene Therapy Porgram (GTP) at the University of Pennsylvania announced an expanded collaboration agreement with Penn spinout, Scout Bio. The agreement will grant Scout Bio exclusive rights, in the field of animal health, to an emerging viral vector capsid technology for use in animal gene therapy, as well as extended option terms to other next-generation AAV vector technologies.
Dr. Jim Wilson, Director of the Gene Therapy Program (GTP) at the University of Pennsylvania, has been recognized by Nature Biotechnology as one of the Top 20 Translational Researchers of 2020.
Dr. Jim Wilson, Director of the Gene Therapy Program at the University of Pennsylvania, recently delivered a virtual lecture as a part of the University of the Sciences in Philadelphia's Bicentennial Symposium. Dr. Wilson's presentation, “The Potential of Gene Therapy for Human Monogenic Diseases," is available to view on-demand.
iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors. The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
Moderna, Inc. and the Institute for Life Changing Medicines announced a new collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1, an ultra-rare disease. The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients.
